Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
Go back to Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)| LOGICVISION (NASDAQ: LGVN) | Delayed: 0.80 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.80 | 52 Week High | $1.62 | |||
| Open | $0.80 | 52 Week Low | $0.35 | |||
| Day High | $0.80 | P/E | N/A | |||
| Day Low | $0.80 | EPS | $-0.17 | |||
| Volume | 520 | |||||
| (NASDAQ: LGVNR) | Delayed: 0.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.00 | 52 Week High | $ | |||
| Open | $2.45 | 52 Week Low | $ | |||
| Day High | $0.00 | P/E | N/A | |||
| Day Low | $0.00 | EPS | $ | |||
| Volume | 23,525,480 | |||||
